
## **Charles E Phelps**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4565812/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Optimal health insurance. Journal of Risk and Insurance, 2023, 90, 213-241.	1.6	16
2	A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE). European Journal of Health Economics, 2022, 23, 433-451.	2.8	14
3	ls the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review. Applied Health Economics and Health Policy, 2021, 19, 155-162.	2.1	12
4	Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach. Value in Health, 2021, 24, 244-249.	0.3	43
5	Estimating optimal willingness to pay thresholds for costâ€effectiveness analysis: A generalized method. Health Economics (United Kingdom), 2021, 30, 1697-1702.	1.7	5
6	Health technology assessment with risk aversion in health. Journal of Health Economics, 2020, 72, 102346.	2.7	41
7	Feasibility of Measuring Preferences for Chemotherapy Among Early-Stage Breast Cancer Survivors Using a Direct Rank Ordering Multicriteria Decision Analysis Versus a Time Trade-Off. Patient, 2020, 13, 557-566.	2.7	2
8	When Opportunity Knocks, What Does It Say?. Value in Health, 2019, 22, 851-853.	0.3	6
9	A New Method to Determine the Optimal Willingness to Pay in Cost-Effectiveness Analysis. Value in Health, 2019, 22, 785-791.	0.3	32
10	Valuing Health: Evolution, Revolution, Resistance, and Reform. Value in Health, 2019, 22, 505-510.	0.3	1
11	Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]. Value in Health, 2018, 21, 131-139.	0.3	321
12	A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health, 2018, 21, 161-165.	0.3	113
13	Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]. Value in Health, 2018, 21, 146-154.	0.3	59
14	Cost Effectiveness of Gene Expression Profile Testing in Community Practice. Journal of Clinical Oncology, 2018, 36, 554-562.	1.6	35
15	Patents and drug insurance: Clash of the Titans?. Science Translational Medicine, 2018, 10, .	12.4	1
16	Resource allocation in decision support frameworks. Cost Effectiveness and Resource Allocation, 2018, 16, 48.	1.5	7
17	Vision for a systems architecture to integrate and transform population health. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12595-12602.	7.1	9
18	Toward Alignment in the Reporting of Economic Evaluations of Diagnostic Tests and Biomarkers: The AGREEDT Checklist. Medical Decision Making, 2018, 38, 778-788.	2.4	6

CHARLES E PHELPS

#	Article	IF	CITATIONS
19	Planning and priority setting for vaccine development and immunization. Vaccine, 2017, 35, A50-A56.	3.8	5
20	Using Multicriteria Approaches to Assess the Value of Health Care. Value in Health, 2017, 20, 251-255.	0.3	28
21	Evaluating Frameworks That Provide Value Measures for Health Care Interventions. Value in Health, 2017, 20, 185-192.	0.3	44
22	Remembering a Giant in Economics: Kenneth J. Arrow (1922–2017). Value in Health, 2017, 20, 999.	0.3	0
23	Beyond cost-effectiveness: Using systems analysis for infectious disease preparedness. Vaccine, 2017, 35, A46-A49.	3.8	13
24	Allocating provider resources to diagnose and treat restless legs syndrome: a cost-utility analysis. Sleep Medicine, 2017, 38, 44-49.	1.6	4
25	Compare voting systems to improve them. Nature, 2017, 541, 151-153.	27.8	7
26	Strategic Planning in Population Health and Public Health Practice: A Call to Action for Higher Education. Milbank Quarterly, 2016, 94, 109-125.	4.4	8
27	Bridging the gap: Need for a data repository to support vaccine prioritization efforts. Vaccine, 2015, 33, B34-B39.	3.8	12
28	1067Multi-Attribute Ranking Tool for Vaccines: Strategic Priority Setting to Support Vaccine Development. Open Forum Infectious Diseases, 2014, 1, S313-S313.	0.9	0
29	Tackling Heterogeneity. Medical Decision Making, 2014, 34, 944-947.	2.4	0
30	A priority-setting aid for new vaccine candidates. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3199-3200.	7.1	13
31	Cost effectiveness of a gene expression score and myocardial perfusion imaging for diagnosis of coronary artery disease. American Heart Journal, 2014, 167, 697-706.e2.	2.7	8
32	A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging The COMPASS Study. Circulation: Cardiovascular Genetics, 2013, 6, 154-162.	5.1	71
33	Clinical Implications of Referral Bias in the Diagnostic Performance of Exercise Testing for Coronary Artery Disease. Journal of the American Heart Association, 2013, 2, e000505.	3.7	35
34	Costs and Clinical Outcomes Associated with Use of Ranolazine for Treatment of Angina. Clinical Therapeutics, 2012, 34, 1395-1407.e4.	2.5	14
35	Economic Issues of Breastfeeding. Breastfeeding Medicine, 2011, 6, 307-311.	1.7	5
36	How do health insurance loading fees vary by group size?: implications for Healthcare reform. International Journal of Health Care Finance and Economics, 2011, 11, 181-207.	1.2	31

CHARLES E PHELPS

#	Article	IF	CITATIONS
37	Economics of Healthcare Financing: Implications for Breastfeeding. Breastfeeding Medicine, 2010, 5, 191-199.	1.7	1
38	25 years of excellence: The Journal of Health Economics in retrospective. Journal of Health Economics, 2007, 26, 1075-1080.	2.7	3
39	Good Technologies Gone Bad. Medical Decision Making, 1997, 17, 107-117.	2.4	23
40	Economic foundations of cost-effectiveness analysis. Journal of Health Economics, 1997, 16, 1-31.	2.7	605
41	Perspectives in health economics. Health Economics (United Kingdom), 1995, 4, 335-353.	1.7	25
42	Diffusion of Information in Medical Care. Journal of Economic Perspectives, 1992, 6, 23-42.	5.9	111
43	On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses. International Journal of Technology Assessment in Health Care, 1991, 7, 12-21.	0.5	145
44	Focusing Technology Assessment Using Medical Decision Theory. Medical Decision Making, 1988, 8, 279-289.	2.4	138